[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540914":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":59,"centralContacts":45,"locations":63,"responsibleParty":84,"collaborators":86,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":45,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":98,"minAge":45,"maxAge":45,"enrollmentInfo":99,"targetDuration":45,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":45,"overallStatus":65,"whyStopped":45,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Roswell Park Cancer Institute","OTHER",[8,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A (MedSupport)","EXPERIMENTAL","Participants receive the MedSupport intervention consisting of three components: universal screening for adherence barriers, tailored virtual education enhancement, and communication of barriers to activate multidisciplinary healthcare teams for 12 months. Participants also use the MEMS device to track oral chemotherapy adherence at baseline and follow-up. Patients also undergo blood sample collection throughout the study.",[13,14,15,16,17],"Procedure: Biospecimen Collection","Other: Electronic Health Record Review","Other: Interview","Other: Medical Device Usage and Evaluation","Other: Survey Administration",{"label":19,"type":20,"description":21,"interventionNames":22},"Arm B (usual care)","ACTIVE_COMPARATOR","Participants receive usual care consisting of medical consultations and supportive care for 12 months. Participants also use the MEMS device to track oral chemotherapy adherence at baseline and follow-up. Patients also undergo blood sample collection throughout the study.",[23,13,14,15,16,17],"Other: Best Practice",[25,32,41,46,49,53,56],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Best Practice","Receive usual care",[19],[30,31],"standard of care","standard therapy",{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"PROCEDURE","Biospecimen Collection","Undergo blood sample collection",[9,19],[38,39,40],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":6,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Electronic Health Record Review","Ancillary studies",[9,19],null,{"type":6,"name":47,"description":43,"armGroupLabels":48,"otherNames":45},"Interview",[9,19],{"type":6,"name":50,"description":51,"armGroupLabels":52,"otherNames":45},"Medical Device Usage and Evaluation","Receive MedSupport intervention",[9],{"type":6,"name":50,"description":54,"armGroupLabels":55,"otherNames":45},"Use MEMS device",[9,19],{"type":6,"name":57,"description":43,"armGroupLabels":58,"otherNames":45},"Survey Administration",[9,19],[60],{"name":61,"affiliation":5,"role":62},"Kara M Kelly","PRINCIPAL_INVESTIGATOR",[64],{"facility":5,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"RECRUITING","Buffalo","New York","14263","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-78.87837,42.88645,{"lat":75,"lon":74},[78,83],{"name":79,"role":80,"phone":81,"phoneExt":45,"email":82},"Kara M. Kelly","CONTACT","716-845-2333","Kara.Kelly@RoswellPark.org",{"name":79,"role":62,"phone":45,"phoneExt":45,"email":45},{"type":85,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR",[87],{"name":88,"class":89},"National Cancer Institute (NCI)","NIH","100540914","medsupport-intervention-to-identify-and-address-barriers-to-pediatric-medication-adherence-100540914",false,"NCT06323044","MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence","MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication Adherence","Inclusion Criteria:\n\n* Parent of a child diagnosed with acute lymphoblastic leukemia (ALL)\n* Child patient age 365 days to \\\u003C 19 years at time of study entry.\n* Parent's child patient's therapy must include 6-mercaptopurine (6-MP) administered orally or by nasogastric (NG) tube.\n* Verbal fluency in English, or Spanish\n* Parent has a smartphone or computer access with an Internet connection.\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* Parent is unwilling or unable to follow protocol requirements.",true,"ALL",{"count":100,"type":101},150,"ESTIMATED","INTERVENTIONAL",[104],"NA","This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medication is a significant public health problem, and rigorous research repeatedly documents that nonadherence increases risk for hospitalization, healthcare cost, disease progression, and death. Pediatric acute lymphoblastic leukemia (ALL) patients who miss 5% of 6-mercaptopurine (6-MP) doses within the 2-year 6-MP regimen have a 2.7-fold risk of cancer that comes back after a period of improvement (relapse). To address these families' needs, researchers have developed MedSupport, a theory-based multilevel intervention with targets at the organizational, healthcare team, and caregiver levels that is designed to address root barriers to medication adherence. This study is being done to better understand families' experiences giving their child oral chemotherapy at home and to help families cope with the day-to-day challenges of giving their child medication.",[107],"Acute Lymphoblastic Leukemia","2026-08-10",{"date":110,"type":111},"2026-08-12","ACTUAL",{"date":113,"type":111},"2025-02-11",{"date":115,"type":101},"2029-03-31",{"name":5,"class":6},1]